Park Jae-Gahb, Kim Duck-Woo, Hong Chang Won, Nam Byung-Ho, Shin Young-Kyoung, Hong Sung-Hye, Kim Il-Jin, Lim Seok-Byung, Aronson Melyssa, Bisgaard Marie Luise, Brown Gregor J, Burn John, Chow Elizabeth, Conrad Peggy, Douglas Fiona, Dunlop Malcolm, Ford James, Greenblatt Marc S, Heikki Jarvinen, Heinimann Karl, Lynch Elly L, Macrae Finlay, McKinnon Wendy C, Möeslein Gabriela, Rossi Benedito Mauro, Rozen Paul, Schofield Lyn, Vaccaro Carlos, Vasen Hans, Velthuizen Mary, Viel Alessandra, Wijnen Juul
Korean Hereditary Tumor Registry, Laboratory of Cell Biology, Cancer Research Institute and Cancer Research Center, Seoul National University College of Medicine, Korea.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3389-93. doi: 10.1158/1078-0432.CCR-05-2452.
The aim of study was to determine the clinical characteristics and mutational profiles of the mismatch repair genes in hereditary nonpolyposis colorectal cancer (HNPCC) patients with small bowel cancer (SBC).
A questionnaire was mailed to 55 members of the International Society for Gastrointestinal Hereditary Tumours, requesting information regarding patients with HNPCC-associated SBC and germ line mismatch repair gene mutations.
The study population consisted of 85 HNPCC patients with identified mismatch repair gene mutations and SBCs. SBC was the first HNPCC-associated malignancy in 14 of 41 (34.1%) patients for whom a personal history of HNPCC-associated cancers was available. The study population harbored 69 different germ line mismatch repair gene mutations, including 31 mutations in MLH1, 34 in MSH2, 3 in MSH6, and 1 in PMS2. We compared the distribution of the mismatch repair mutations in our study population with that in a control group, including all pathogenic mismatch repair mutations of the International Society for Gastrointestinal Hereditary Tumours database (excluding those in our study population). In patients with MSH2 mutations, patients with HNPCC-associated SBCs had fewer mutations in the MutL homologue interaction domain (2.9% versus 19.9%, P = 0.019) but an increased frequency of mutations in codons 626 to 733, a domain that has not previously been associated with a known function, versus the control group (26.5% versus 2.8%, P < 0.001).
In HNPCC patients, SBC can be the first and only cancer and may develop as soon as the early teens. The distribution of MSH2 mutations found in patients with HNPCC-associated SBCs significantly differed from that found in the control group (P < 0.001).
本研究旨在确定遗传性非息肉病性结直肠癌(HNPCC)合并小肠癌(SBC)患者错配修复基因的临床特征和突变谱。
向国际胃肠道遗传性肿瘤学会的55名成员邮寄了一份问卷,要求提供有关HNPCC相关SBC患者及种系错配修复基因突变的信息。
研究人群包括85例已确定有错配修复基因突变和SBC的HNPCC患者。在41例有HNPCC相关癌症个人史的患者中,有14例(34.1%)的SBC是首个与HNPCC相关的恶性肿瘤。研究人群中有69种不同的种系错配修复基因突变,包括MLH1基因的31种突变、MSH2基因的34种突变、MSH6基因的3种突变和PMS2基因的1种突变。我们将研究人群中错配修复突变的分布与一个对照组进行了比较,该对照组包括国际胃肠道遗传性肿瘤学会数据库中的所有致病性错配修复突变(不包括我们研究人群中的突变)。在MSH2基因突变的患者中,HNPCC相关SBC患者在MutL同源物相互作用域的突变较少(2.9%对19.9%,P = 0.019),但与对照组相比,密码子626至733区域的突变频率增加,该区域以前未与已知功能相关联(26.5%对2.8%,P < 0.001)。
在HNPCC患者中,SBC可能是首个也是唯一的癌症,可能在青少年早期就会发生。HNPCC相关SBC患者中发现的MSH2基因突变分布与对照组显著不同(P < 0.001)。